A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
Alan Hilary Calvert
Research Funding - Basilea
Michael Gonzalez
No relevant relationships to disclose
Sushila Ganguli
No relevant relationships to disclose
Matthew Ng
No relevant relationships to disclose
Sarah Benafif
Research Funding - Basilea
Marta Capelan
No relevant relationships to disclose
Robert Goldstein
No relevant relationships to disclose
Krunal Shah
No relevant relationships to disclose
Claire Jarvis
No relevant relationships to disclose
Michael Flynn
No relevant relationships to disclose
Martin Forster
No relevant relationships to disclose
Stephanie Anderson
Employment or Leadership Position - Basilea
Anne Schmitt-Hoffman
Employment or Leadership Position - Basilea
Stock Ownership - Basilea (I)
Research Funding - Basilea (I)
Heidi Lane
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Research Funding - Basilea
Marc Engelhardt
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Alison L. Hannah
Consultant or Advisory Role - Basilea (U)
Alexandar Tzankov
Research Funding - Basilea
Felix Bachmann
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Research Funding - Basilea
L Rhoda Molife
Research Funding - Basilea
Rebecca Kristeleit
Research Funding - Basilea